Войти в систему Зарегистрироваться бесплатно

NeuroVive Pharmaceutical AB Доход

Что обозначает Доход в NeuroVive Pharmaceutical AB?

Доход NeuroVive Pharmaceutical AB является -kr104.56

Какое определение для Доход?

Чистая прибыль, подлежащая распределению среди обычных акционеров, равна чистой прибыли за вычетом выплаченных привилегированных дивидендов.

Net income available to common shareholders are the profits remaining after the company pays all of its suppliers, employees, service providers, creditors, and preferred shareholders. In other words, this is revenue less all expenses and preferred dividends. The number measures common shareholders' claim on the company's cash flows.

Доход компаний в Health Care сектор на OTC по сравнению с NeuroVive Pharmaceutical AB

Что делает NeuroVive Pharmaceutical AB?

Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

Компании с доход похож на NeuroVive Pharmaceutical AB